Skip to main content

Table 5 Perinatal and neonatal mortality by anti-malarial drug exposure during first trimester

From: Exposure to artemether-lumefantrine (Coartem®) in first trimester pregnancy in an observational study in Zambia

 

Exposure group

Outcome of deliveries (N*)

AL only, N=135, n (%), (95% CI)

AL and SP, N=7, n (%), (95% CI)

SP and/or quinine, N=129, n (%), (95% CI)

No anti-malarial, N=644, n (%), (95% CI)

Unknown anti-malarial, N=40, n (%), (95% CI)

Perinatal mortality, n (%)

6 (4.4)

1 (14.3)

5 (3.9)

31 (4.8)

1 (2.5)

(2.1, 9.4)

(2.6. 51.3)

(1.7, 8.8)

(3.4, 6.8)

(0.4, 12.9)

Stillbirth (>28 weeks gestation), n (%)

2 (1.5)

0 (0)

3 (2.3)

17 (2.6)

0 (0)

(0.4, 5.2)

(0.0, 39.0)

(0.8, 6.6)

(1.7, 4.2)

(0.0, 9.0)

Death ≤7 days after birth, n (%)

4 (3.0)

1 (14.3)

2 (1.6)

14 (2.2)

1 (2.5)

(1.2, 7.4)

(2.6, 51.3)

(0.4, 5.5)

(1.3, 3.6)

(0.4, 12.9)

 

Exposure group

Outcome of neonates (N )

AL only, N=133, n (%), (95% CI)

AL and SP, N=7, n (%), (95% CI)

SP and/or quinine, N=126, n (%), (95% CI)

No anti-malarial, N=627, n (%), (95% CI)

Unknown anti-malarial, N=40, n (%), (95% CI)

Neonatal mortality within 28 days of birth, n (%)

5 (3.8)

1 (14.3)

2 (1.6)

19 (3.0)

1 (2.5)

(1.6, 8.5)

(2.6, 51.3)

(0.4, 5.6)

(1.9, 4.7)

(0.4, 12.9)

Infant mortality >28 days to 1 year afer birth n (%)

8 (6.3)

0 (0.0)

1 (0.8)

21 (3.5)

0 (0.0)

(3.2, 11.9)

(0.0, 39.0)

(0.1, 4.4)

(2.3, 5.2)

(0.0, 9.0)

Total infant mortality within 1 year after birth, n (%)

13 (9.8)

1 (14.3)

3 (2.4)

40 (6.4)

1 (2.5)

(5.8, 16.0)

(2.6, 51.3)

(0.8, 6.8)

(4.7, 8.6)

(0.4, 12.9)

  1. Perinatal mortality: stillbirth or early neonatal death within 7 days after birth; CI = confidence interval.
  2. *All deliveries; Total live births; Denominators: AL only N=128; AL and SP N=6; SP and/or quinine N=124; No anti-malarial N=608; and Unknown anti-malarial N=39.